DIANTHUS THERAPEUTICS INC (DNTH) Stock Price, Quote, News and Overview
NASDAQ:DNTH - Nasdaq - US2528281080 - Common Stock - Currency: USD
DNTH Quote, Performance and Key Statistics
17.39
-0.46 (-2.58%)
The current stock price of DNTH is 17.39 USD. In the past month the price decreased by -19.86%. In the past year, price decreased by -19.53%.
DNTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 99.7 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About DNTH
Company Profile
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Company Info
DIANTHUS THERAPEUTICS INC
7 Times Square, 43Rd Floor
New York City NEW YORK US
Employees: 78
Phone: 19299994055
DIANTHUS THERAPEUTICS INC / DNTH FAQ
What is the stock price of DIANTHUS THERAPEUTICS INC today?
The current stock price of DNTH is 17.39 USD. The price decreased by -2.58% in the last trading session.
What is the ticker symbol for DIANTHUS THERAPEUTICS INC stock?
The exchange symbol of DIANTHUS THERAPEUTICS INC is DNTH and it is listed on the Nasdaq exchange.
On which exchange is DNTH stock listed?
DNTH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DIANTHUS THERAPEUTICS INC stock?
18 analysts have analysed DNTH and the average price target is 50.09 USD. This implies a price increase of 188.06% is expected in the next year compared to the current price of 17.39. Check the DIANTHUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DIANTHUS THERAPEUTICS INC worth?
DIANTHUS THERAPEUTICS INC (DNTH) has a market capitalization of 559.26M USD. This makes DNTH a Small Cap stock.
How many employees does DIANTHUS THERAPEUTICS INC have?
DIANTHUS THERAPEUTICS INC (DNTH) currently has 78 employees.
What are the support and resistance levels for DIANTHUS THERAPEUTICS INC (DNTH) stock?
DIANTHUS THERAPEUTICS INC (DNTH) has a support level at 17.17 and a resistance level at 19.69. Check the full technical report for a detailed analysis of DNTH support and resistance levels.
Is DIANTHUS THERAPEUTICS INC (DNTH) expected to grow?
The Revenue of DIANTHUS THERAPEUTICS INC (DNTH) is expected to decline by -41.8% in the next year. Check the estimates tab for more information on the DNTH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DIANTHUS THERAPEUTICS INC (DNTH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DNTH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DNTH, evaluating the profitability, health, valuation and growth aspects
- DIANTHUS THERAPEUTICS INC (DNTH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DIANTHUS THERAPEUTICS INC (DNTH) Sales and EPS estimates to see what analysts future expectations are.
- DIANTHUS THERAPEUTICS INC (DNTH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DIANTHUS THERAPEUTICS INC (DNTH) Insider and Institutional Ownership to learn about the owners and their transactions.
- DIANTHUS THERAPEUTICS INC (DNTH) Stock Chart to make your own analysis
- DIANTHUS THERAPEUTICS INC (DNTH) Latest news and press-releases to stay up to date.
Does DIANTHUS THERAPEUTICS INC (DNTH) stock pay dividends?
DNTH does not pay a dividend.
When does DIANTHUS THERAPEUTICS INC (DNTH) report earnings?
DIANTHUS THERAPEUTICS INC (DNTH) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of DIANTHUS THERAPEUTICS INC (DNTH)?
DIANTHUS THERAPEUTICS INC (DNTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).
What is the Short Interest ratio of DIANTHUS THERAPEUTICS INC (DNTH) stock?
The outstanding short interest for DIANTHUS THERAPEUTICS INC (DNTH) is 20.97% of its float. Check the ownership tab for more information on the DNTH short interest.
DNTH Technical Analysis
DNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNTH. No worries on liquidiy or solvency for DNTH as it has an excellent financial health rating, but there are worries on the profitability.
DNTH Financial Highlights
Over the last trailing twelve months DNTH reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS increased by 50.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.9% | ||
| ROE | -30.65% | ||
| Debt/Equity | 0 |
DNTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to DNTH. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -30.93% and a revenue growth -41.8% for DNTH